FOLH1 and metastatic neoplasm: In this setting, the current European guidelines recommend a PSMA PET/CT scan in case of PSA > 0.2 ng/mL to rule out metastatic disease [1]; the PI-RR could be used as an adjunct to PSMA PET/CT for patients with high clinical suspicion of local recurrence.